Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation
Advanced Science · 2025
DOI: 10.1002/advs.202508111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Shudi Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Pancreatic Disease, Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Med…. Hauptthemen laut MEDLINE: Lipogenesis, Peptides, Sterol Regulatory Element Binding Protein 1, Sterol Regulatory Element Binding Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Center of Technology Innovation for Biopharmaceuticals, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Tumor cells have substantially increased lipid biogenesis, which is primarily regulated by the activation of sterol regulatory element‐binding protein (SREBP). However, whether SREBP regulation can be targeted for cancer treatment remains unclear. Here, it is demonstrated that treating tumor cells with a peptide that replicates the amino acid sequence in Insig1/2 loop 1, which is the region where Insig1/2 interacts with AKT‐phosphorylated phosphoenolpyruvate carboxykinase 1 (PCK1), inhibits the IGF1‐induced interaction between PCK1 and Insig1/2. Consequently, this treatment abrogates PCK1‐mediated phosphorylation of Insig1 at S207 and Insig2 at S151, reduces the nuclear accumulation of SREBP1, and decreases SREBP1 activity‐dependent expression of lipid synthesis genes, lipid accumulation, and tumor cell proliferation. Intravenous administration of engineered liposomal nanoparticles (LNP)‐encapsulated Insig1/2 loop 1 peptide effectively suppresses tumor growth and extends mouse survival without apparent adverse effects. The peptide treatment, when combined with the receptor tyrosine kinase inhibitor lenvatinib or the anti‐obesity medication semaglutide, results in additive tumor inhibition. These findings highlight the potential of LNP‐Insig1/2 loop 1 peptide administration to inhibit SREBP activity—traditionally regarded as untargetable—for the treatment of human cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Pancreatic Disease, Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicin…
- Institute of Fundamental and Transdisciplinary Research, Cancer Center, Zhejiang University, Hangzhou, Zhejiang, 310029, China.
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027, China.
ORCID-Profile: Zhimin Lu
Förderung
- National Natural Science Foundation of China
- National Center of Technology Innovation for Biopharmaceuticals
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Luo, S., Yang, H., Jiang, X., Wang, Z., He, X., Meng, Y., Li, S., Li, M., Xu, D., Mao, Z., & Lu, Z. (2025). Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation. Advanced Science. https://doi.org/10.1002/advs.202508111
Vancouver
Luo S, Yang H, Jiang X, Wang Z, He X, Meng Y, et al. Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation. Advanced Science. 2025. doi:10.1002/advs.202508111
BibTeX
@article{Luo2025,
author = {Luo, Shudi and Yang, Huang and Jiang, Xiaoming and Wang, Zheng and He, Xuxiao and Meng, Ying and Li, Shan and Li, Min and Xu, Daqian and Mao, Zhengwei and Lu, Zhimin},
title = {Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202508111}
}
EUVIMED